Spine Infection
Conditions
Keywords
MRI, CLIAVIST, MACROPHAGE, INFECTION, SPINE
Brief summary
USPIO contrast enhancement results from intracellular trapping of the iron particles in reactive cells, especially macrophages. 17FDG-PET studies have demonstrated that macrophages are present in spine infectious diseases but are absent in spine degenerative diseases. The aim of this work is to compare the enhancement induced by CLIAVIST in both diseases. The absence of macrophages in degenerative lesions should help to differentiate them from infectious lesions, who should present contrast enhancement in relation to the presence of macrophages.
Interventions
DRUGCliavist
Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight \> 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
Sponsors
University Hospital, Strasbourg, France
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* spine infection or spine degenerative disease * patient agreement obtained
Exclusion criteria
* pregnancy * MRI contra-indications * cliavist contra-indication * dextran allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First MRI: performed immediately after gadolinium administration | immediately after gadolinium administration |
| Second MRI: performed 24 hours after cliavist administration | 24 hours after cliavist administration |
Countries
France
Contacts
Primary ContactJean-Louis Dietemann, MD
Backup ContactStéphane Kremer, MD
Outcome results
None listed